Effectiveness and Safety of Switching from Innovator Infliximab to Biosimilar CT-P13 in Inflammatory Rheumatic Diseases: A Real-World Case Study
Por:
Vergara-Dangond C, Sáez Belló M, Climente Martí M, Llopis Salvia P and Alegre-Sancho JJ
Publicada:
1 sep 2017
Ahead of Print:
30 jun 2017
Categoría:
Pharmacology
Resumen:
Objective CT-P13 is a biosimilar with comparable pharmacokinetics, efficacy and safety to its reference product (RP), infliximab. Studies have shown that switching from RP to CT-P13 does not reduce the effectiveness or safety of treatment.
Methods In this retrospective real-world study, patients with inflammatory diseases treated with RP were switched to CT-P13 (n = 7) or continued on RP (n = 6). Clinical outcomes were compared between groups after four treatment cycles.
Results CT-P13 demonstrated comparable effectiveness to its RP. All patients who switched to the biosimilar maintained or improved their clinical response, including two who remained in remission and three who moved into remission. In the RP group, five patients maintained their clinical response, with one achieving remission. Safety profiles were similar between groups.
Conclusions CT-P13 was equally effective as infliximab RP in this real-world study. CT-P13 is a valid, lower-cost alternative for patients currently receiving RP.
Filiaciones:
:
Department of Rheumatology, Doctor Peset University Hospital, Gaspar Aguilar Avenue 90, 46017, Valencia, Spain
:
Foundation for the Promotion of Health and Biomedical Research of the Valencian Community (FISABIO), Valencia, Spain
:
Pharmacy Service, Doctor Peset University Hospital, Valencia, Spain
:
Pharmacy Service, Doctor Peset University Hospital, Valencia, Spain
:
Department of Rheumatology, Doctor Peset University Hospital, Gaspar Aguilar Avenue 90, 46017, Valencia, Spain.
gold, Green Published
|